Barclays has maintained an “overweight” rating on a U.S. small-cap biotechnology stock, setting a price target of $157, after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE